BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 30213946)

  • 1. A small molecule targeting myoferlin exerts promising anti-tumor effects on breast cancer.
    Zhang T; Li J; He Y; Yang F; Hao Y; Jin W; Wu J; Sun Z; Li Y; Chen Y; Yi Z; Liu M
    Nat Commun; 2018 Sep; 9(1):3726. PubMed ID: 30213946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modification and Biological Evaluation of a Series of 1,5-Diaryl-1,2,4-triazole Compounds as Novel Agents against Pancreatic Cancer Metastasis through Targeting Myoferlin.
    Li Y; He Y; Shao T; Pei H; Guo W; Mi D; Krimm I; Zhang Y; Wang P; Wang X; Liu M; Yi Z; Chen Y
    J Med Chem; 2019 May; 62(10):4949-4966. PubMed ID: 31026162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Emerging Therapeutic Approach by Targeting Myoferlin (MYOF) for Malignant Tumors.
    Gu H; Peng Y; Chen Y
    Curr Top Med Chem; 2020; 20(17):1509-1515. PubMed ID: 32552653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A potent and selective small molecule inhibitor of myoferlin attenuates colorectal cancer progression.
    He Y; Kan W; Li Y; Hao Y; Huang A; Gu H; Wang M; Wang Q; Chen J; Sun Z; Liu M; Chen Y; Yi Z
    Clin Transl Med; 2021 Feb; 11(2):e289. PubMed ID: 33634965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 1,5-diaryl-1,2,4-triazole derivatives as myoferlin inhibitors and their antitumor effects in pancreatic cancer.
    Gu H; Zhang T; Li Y; He Y; Guan T; Kan W; He P; Yi Z; Chen Y
    Future Med Chem; 2022 Oct; 14(20):1425-1440. PubMed ID: 36165130
    [No Abstract]   [Full Text] [Related]  

  • 6. Loss of myoferlin redirects breast cancer cell motility towards collective migration.
    Volakis LI; Li R; Ackerman WE; Mihai C; Bechel M; Summerfield TL; Ahn CS; Powell HM; Zielinski R; Rosol TJ; Ghadiali SN; Kniss DA
    PLoS One; 2014; 9(2):e86110. PubMed ID: 24586247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myoferlin is a key regulator of EGFR activity in breast cancer.
    Turtoi A; Blomme A; Bellahcène A; Gilles C; Hennequière V; Peixoto P; Bianchi E; Noel A; De Pauw E; Lifrange E; Delvenne P; Castronovo V
    Cancer Res; 2013 Sep; 73(17):5438-48. PubMed ID: 23864327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myoferlin, a Membrane Protein with Emerging Oncogenic Roles.
    Dong Y; Kang H; Liu H; Wang J; Guo Q; Song C; Sun Y; Zhang Y; Zhang H; Zhang Z; Guan H; Fang Z; Li F
    Biomed Res Int; 2019; 2019():7365913. PubMed ID: 31828126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myoferlin depletion in breast cancer cells promotes mesenchymal to epithelial shape change and stalls invasion.
    Li R; Ackerman WE; Mihai C; Volakis LI; Ghadiali S; Kniss DA
    PLoS One; 2012; 7(6):e39766. PubMed ID: 22761893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High expression of myoferlin is associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with HPV-status.
    Kumar B; Brown NV; Swanson BJ; Schmitt AC; Old M; Ozer E; Agrawal A; Schuller DE; Teknos TN; Kumar P
    Oncotarget; 2016 Apr; 7(14):18665-77. PubMed ID: 26919244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
    Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
    Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. iTRAQ-based quantitative proteomics reveals myoferlin as a novel prognostic predictor in pancreatic adenocarcinoma.
    Wang WS; Liu XH; Liu LX; Lou WH; Jin DY; Yang PY; Wang XL
    J Proteomics; 2013 Oct; 91():453-65. PubMed ID: 23851313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of oxaliplatin-resistant gastric cancer organoids: importance of myoferlin in the acquisition of oxaliplatin resistance.
    Harada K; Sakamoto N; Ukai S; Yamamoto Y; Pham QT; Taniyama D; Honma R; Maruyama R; Takashima T; Ota H; Takemoto Y; Tanabe K; Ohdan H; Yasui W
    Gastric Cancer; 2021 Nov; 24(6):1264-1277. PubMed ID: 34272617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic modeling of the effects of myoferlin on tumor cell invasion.
    Eisenberg MC; Kim Y; Li R; Ackerman WE; Kniss DA; Friedman A
    Proc Natl Acad Sci U S A; 2011 Dec; 108(50):20078-83. PubMed ID: 22135466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knockdown of Myoferlin Suppresses Migration and Invasion in Clear-Cell Renal-Cell Carcinoma.
    Cox A; Zhao C; Tolkach Y; Nettersheim D; Schmidt D; Kristiansen G; Mueller SC; Ritter M; Hauser S; Ellinger J
    Anticancer Res; 2020 Jun; 40(6):3119-3128. PubMed ID: 32487606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of breast cancer metastases by a novel inhibitor of TGFβ receptor 1.
    Fang Y; Chen Y; Yu L; Zheng C; Qi Y; Li Z; Yang Z; Zhang Y; Shi T; Luo J; Liu M
    J Natl Cancer Inst; 2013 Jan; 105(1):47-58. PubMed ID: 23178439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PINCH-1 interacts with myoferlin to promote breast cancer progression and metastasis.
    Qian T; Liu C; Ding Y; Guo C; Cai R; Wang X; Wang R; Zhang K; Zhou L; Deng Y; Wu C; Sun Y
    Oncogene; 2020 Mar; 39(10):2069-2087. PubMed ID: 31801973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic inhibition of breast cancer bone metastasis progression and lung colonization: breaking the vicious cycle by targeting α5β1 integrin.
    Yao H; Veine DM; Livant DL
    Breast Cancer Res Treat; 2016 Jun; 157(3):489-501. PubMed ID: 27255534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating breast cancer metastasis with cabazitaxel-loaded polymeric micelles.
    Zhong T; He B; Cao HQ; Tan T; Hu HY; Li YP; Zhang ZW
    Acta Pharmacol Sin; 2017 Jun; 38(6):924-930. PubMed ID: 28504249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myoferlin regulates cellular lipid metabolism and promotes metastases in triple-negative breast cancer.
    Blomme A; Costanza B; de Tullio P; Thiry M; Van Simaeys G; Boutry S; Doumont G; Di Valentin E; Hirano T; Yokobori T; Gofflot S; Peulen O; Bellahcène A; Sherer F; Le Goff C; Cavalier E; Mouithys-Mickalad A; Jouret F; Cusumano PG; Lifrange E; Muller RN; Goldman S; Delvenne P; De Pauw E; Nishiyama M; Castronovo V; Turtoi A
    Oncogene; 2017 Apr; 36(15):2116-2130. PubMed ID: 27775075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.